MERYX

Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancers such as leukemia, lung cancer, and melanoma. It offers potent inhibitors of MerTK, such as MRX-2843, a clinical drug candidate; and MRX-6313, a backup candidate that inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies. Meryx was founded in 2013 and is based in Chapel Hill, North Carolina.